Assessment of health-related quality of life (HRQL) in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 (C20) vs 25mg/m2 (C25) in post-docetaxel (D) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

MLA

Eisenberger, M., et al. Assessment of Health-Related Quality of Life (HRQL) in PROSELICA: A Phase 3 Trial Assessing Cabazitaxel 20 Mg/M2 (C20) vs 25mg/M2 (C25) in Post-Docetaxel (D) Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (MCRPC). Jan. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.RECOLECTA.....6eaaafe10e7e5daab47a57737e7e0d72&authtype=sso&custid=ns315887.

APA

Eisenberger, M., Hardy-Bessard, A., Kim, C., Geczi, L., Ford, D., Mourey, L., Carles, J., Parente, P., Font, A., Kacso, G., Barnes, G., Wang, H., Zhang, W., Ozatilgan, A., & de Bono, J. (2017). Assessment of health-related quality of life (HRQL) in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 (C20) vs 25mg/m2 (C25) in post-docetaxel (D) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Chicago

Eisenberger, M, Ac Hardy-Bessard, Cs Kim, L Geczi, D Ford, L Mourey, J Carles, et al. 2017. “Assessment of Health-Related Quality of Life (HRQL) in PROSELICA: A Phase 3 Trial Assessing Cabazitaxel 20 Mg/M2 (C20) vs 25mg/M2 (C25) in Post-Docetaxel (D) Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (MCRPC),” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.RECOLECTA.....6eaaafe10e7e5daab47a57737e7e0d72&authtype=sso&custid=ns315887.